Malabsorption
RecruitingStudy on the Safety of ELGN-2112 for Preterm Infants with Intestinal Malabsorption
- Disease:Malabsorption
- Substances:Insulin Human
Austria- Participants:0–17 years
- Substances:Insulin Human
- Sponsor:Elgan Pharma Ltd.
Rare diseases
Investigational molecules
Locations
13 Wadi El Haj, 1603100
Elgan Pharma Ltd. focuses on intestinal malabsorption in preterm infants, with clinical research centered on digestive function in very early life and the challenges associated with immature intestinal absorption.
The sponsor’s research activity also addresses the transition to full enteral feeding and the nutritional needs of infants with markedly limited gestational maturity.
Elgan Pharma Ltd. runs clinical trials in conditions such as Malabsorption, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Austria
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.